• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芳烃受体(AhR)与信号转导及转录激活因子3(STAT3):化学致癌过程中的危险组合。

AhR and STAT3: A Dangerous Duo in Chemical Carcinogenesis.

作者信息

Minacori Marco, Fiorini Sara, Perugini Monia, Iannetta Annamaria, Meschiari Giorgia, Chichiarelli Silvia, Altieri Fabio, Natali Pier Giorgio, Eufemi Margherita

机构信息

Department of Biochemical Science "A. Rossi Fanelli", Faculty of Pharmacy and Medicine, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.

Department of Bioscience and Agro-Food and Environmental Technology, University of Teramo, Campus "Aurelio Saliceti", Via R. Balzarini 1, 64100 Teramo, Italy.

出版信息

Int J Mol Sci. 2025 Mar 18;26(6):2744. doi: 10.3390/ijms26062744.

DOI:10.3390/ijms26062744
PMID:40141386
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11943011/
Abstract

Human chemical carcinogenesis is a multistage process where chemicals or their metabolites cause irreversible changes in normal cell physiology, eventually leading to uncontrolled proliferation, transforming a normal cell into a cancerous one. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that regulates cell proliferation, differentiation, apoptosis, angiogenesis, inflammation, and immune responses. Its aberrant activation triggers tumor progression by promoting the expression of oncogenic genes; thus, STAT3 is classified as an oncoprotein. The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that responds to a wide variety of chemicals, including carcinogens like dioxins, inducing genes associated with detoxification, proliferation, and immune regulation. Recent reports show that AhR plays a critical role in cancer development and maintenance. AhR may interact with signaling pathways, like the STAT3 pathway, which mediates the carcinogenic effects of several pollutants. Various chemical agents, such as industrial waste and hydrocarbon compounds, can alter the expression or signaling activity of AhR and STAT3 pathways, leading to different types of cancers. Understanding the complex STAT3-AhR network in the regulation of chemical carcinogenesis could open new avenues for cancer prevention or treatment, particularly in personalized medicine, aiming to improve life expectancy and achieving a complete cure.

摘要

人类化学致癌作用是一个多阶段过程,在此过程中,化学物质或其代谢产物会导致正常细胞生理发生不可逆变化,最终导致不受控制的增殖,将正常细胞转变为癌细胞。信号转导和转录激活因子3(STAT3)是一种细胞质转录因子,可调节细胞增殖、分化、凋亡、血管生成、炎症和免疫反应。其异常激活通过促进致癌基因的表达来触发肿瘤进展;因此,STAT3被归类为一种癌蛋白。芳烃受体(AhR)是一种配体激活的转录因子,可对多种化学物质作出反应,包括二恶英等致癌物,诱导与解毒、增殖和免疫调节相关的基因。最近的报告表明,AhR在癌症发展和维持中起关键作用。AhR可能与信号通路相互作用,如STAT3通路,该通路介导几种污染物的致癌作用。各种化学物质,如工业废物和碳氢化合物,可改变AhR和STAT3通路的表达或信号活性,导致不同类型的癌症。了解化学致癌作用调控中复杂的STAT3-AhR网络可能为癌症预防或治疗开辟新途径,特别是在个性化医学中,旨在提高预期寿命并实现完全治愈。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ab/11943011/88fc21314ce2/ijms-26-02744-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ab/11943011/e05f69333db4/ijms-26-02744-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ab/11943011/88fc21314ce2/ijms-26-02744-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ab/11943011/e05f69333db4/ijms-26-02744-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ab/11943011/88fc21314ce2/ijms-26-02744-g002.jpg

相似文献

1
AhR and STAT3: A Dangerous Duo in Chemical Carcinogenesis.芳烃受体(AhR)与信号转导及转录激活因子3(STAT3):化学致癌过程中的危险组合。
Int J Mol Sci. 2025 Mar 18;26(6):2744. doi: 10.3390/ijms26062744.
2
Aryl hydrocarbon receptor mediates Jak2/STAT3 signaling for non-small cell lung cancer stem cell maintenance.芳基烃受体介导 Jak2/STAT3 信号通路促进非小细胞肺癌干细胞的自我更新。
Exp Cell Res. 2020 Nov 1;396(1):112288. doi: 10.1016/j.yexcr.2020.112288. Epub 2020 Sep 14.
3
Deciphering the roles of aryl hydrocarbon receptor (AHR) in regulating carcinogenesis.解析芳香烃受体(AHR)在调节致癌作用中的角色。
Toxicology. 2023 Aug 15;495:153596. doi: 10.1016/j.tox.2023.153596. Epub 2023 Jul 20.
4
ASC-associated inflammation promotes cecal tumorigenesis in aryl hydrocarbon receptor-deficient mice.ASC 相关炎症促进芳香烃受体缺陷型小鼠盲肠肿瘤的发生。
Carcinogenesis. 2013 Jul;34(7):1620-7. doi: 10.1093/carcin/bgt083. Epub 2013 Mar 1.
5
Down-regulation of aryl hydrocarbon receptor intensifies carcinogen-induced retinal lesion via SOCS3-STAT3 signaling.下调芳香烃受体通过 SOCS3-STAT3 信号加剧致癌物诱导的视网膜损伤。
Cell Biol Toxicol. 2020 Jun;36(3):223-242. doi: 10.1007/s10565-019-09499-z. Epub 2019 Nov 20.
6
The interleukin-6-type cytokine oncostatin M induces aryl hydrocarbon receptor expression in a STAT3-dependent manner in human HepG2 hepatoma cells.白细胞介素-6 型细胞因子肿瘤坏死因子样弱诱导剂 M 以 STAT3 依赖的方式诱导人 HepG2 肝癌细胞中芳香烃受体的表达。
FEBS J. 2013 Dec;280(24):6681-90. doi: 10.1111/febs.12571. Epub 2013 Nov 11.
7
Aryl Hydrocarbon Receptor: Its Regulation and Roles in Transformation and Tumorigenesis.芳烃受体:其在转化和肿瘤发生中的调节和作用。
Curr Drug Targets. 2019;20(6):625-634. doi: 10.2174/1389450120666181109092225.
8
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.人类癌症中组成型吲哚胺2,3-双加氧酶(IDO)的表达由一个涉及白细胞介素-6(IL-6)、信号转导和转录激活因子3(STAT3)以及芳香烃受体(AHR)的自分泌信号回路维持。
Oncotarget. 2014 Feb 28;5(4):1038-51. doi: 10.18632/oncotarget.1637.
9
Aryl Hydrocarbon Receptor Modulates Carcinogenesis and Maintenance of Skin Cancers.芳烃受体调节皮肤癌的发生和维持。
Front Med (Lausanne). 2019 Sep 4;6:194. doi: 10.3389/fmed.2019.00194. eCollection 2019.
10
Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4.配体非依赖性芳烃受体通过降解Smad4抑制肺癌细胞侵袭。
Cancer Lett. 2016 Jul 1;376(2):211-7. doi: 10.1016/j.canlet.2016.03.052. Epub 2016 Apr 6.

本文引用的文献

1
Ruxolitinib enhances gastric cancer to chemotherapy by suppressing JAK/STAT3 and inducing mitochondrial dysfunction and oxidative stress.芦可替尼通过抑制JAK/STAT3以及诱导线粒体功能障碍和氧化应激来增强胃癌对化疗的敏感性。
Immunopharmacol Immunotoxicol. 2025 Apr;47(2):263-271. doi: 10.1080/08923973.2025.2470344. Epub 2025 Feb 26.
2
Aberrant Energy Metabolism in Tumors and Potential Therapeutic Targets.肿瘤中异常的能量代谢及潜在的治疗靶点。
Genes Chromosomes Cancer. 2024 Nov;63(11):e70008. doi: 10.1002/gcc.70008.
3
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer.
色氨酸代谢与信号转导在癌症中的分子机制及其治疗意义。
Mol Cancer. 2024 Oct 30;23(1):241. doi: 10.1186/s12943-024-02164-y.
4
Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms.用于治疗骨髓增殖性肿瘤的下一代 Janus 激酶 2(JAK2)抑制剂的设计与发现进展。
Expert Opin Drug Discov. 2024 Dec;19(12):1403-1415. doi: 10.1080/17460441.2024.2417368. Epub 2024 Oct 16.
5
The Dual Faces of Oestrogen: The Impact of Exogenous Oestrogen on the Physiological and Pathophysiological Functions of Tissues and Organs.雌激素的双重面孔:外源性雌激素对组织和器官生理及病理生理功能的影响。
Int J Mol Sci. 2024 Jul 26;25(15):8167. doi: 10.3390/ijms25158167.
6
Comprehensive investigation of the mutagenic potential of six pesticides classified by IARC as probably carcinogenic to humans.对国际癌症研究机构(IARC)归类为可能对人类致癌的六种农药的致突变潜力进行全面调查。
Chemosphere. 2024 Aug;362:142700. doi: 10.1016/j.chemosphere.2024.142700. Epub 2024 Jun 25.
7
STAT3 Pathways Contribute to β-HCH Interference with Anticancer Tyrosine Kinase Inhibitors.STAT3 通路有助于β-六氯环己烷干扰抗癌酪氨酸激酶抑制剂。
Int J Mol Sci. 2024 Jun 4;25(11):6181. doi: 10.3390/ijms25116181.
8
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
9
Structural determinants of mitochondrial STAT3 targeting and function.线粒体 STAT3 靶向作用及功能的结构决定因素。
Mitochondrial Commun. 2024;2:1-13. doi: 10.1016/j.mitoco.2024.01.001. Epub 2024 Jan 10.
10
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.解析 STAT3 在癌症中的复杂性:分子理解与药物发现。
J Exp Clin Cancer Res. 2024 Jan 20;43(1):23. doi: 10.1186/s13046-024-02949-5.